Lacosamide Zentiva

Lacosamide, the active ingredient in Lacosamide Zentiva, is a sodium channel blocker presented as an oral tablet for oral use. It is used as adjunctive therapy for partial‑onset seizures in patients with epilepsy. GNH USA supplies Lacosamide Zentiva as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Lacosamide is an anticonvulsant that acts on neuronal sodium channels to control seizure activity.

Partial‑onset seizures: used as adjunctive therapy to reduce seizure frequency in patients with epilepsy.

Lacosamide may cause a range of adverse reactions, from mild to serious. Monitoring and reporting are essential for patient safety.

Common Side Effects: - Dizziness: sensation of light‑headedness or unsteadiness. - Nausea: mild to moderate stomach upset. - Fatigue: feeling unusually tired or weak. - Headache: mild to moderate pain in the head. - Tremor: involuntary shaking of limbs. - Diplopia: occasional double vision.

Serious or Rare Side Effects: - Cardiac arrhythmia: irregular heart rhythm, potentially life‑threatening. - Severe skin reactions: such as Stevens‑Johnson syndrome or toxic epidermal necrolysis. - Suicidal thoughts: emergence of depressive symptoms or suicidal ideation. - Hypersensitivity: anaphylactic reactions including swelling, rash, or breathing difficulty.

Before initiating Lacosamide therapy, consider the following safety measures. - Renal impairment: adjust dosing and monitor renal function. - Hepatic impairment: use caution and assess liver enzymes regularly. - Cardiac history: evaluate baseline ECG and monitor for PR‑interval changes. - Concomitant CNS depressants: assess for additive sedation or dizziness. - Pregnancy and lactation: discuss potential risks with a healthcare professional. - Store at ambient temperature: keep below 25°C in the original packaging, protect from moisture.

Lacosamide can interact with other medicines, altering its effectiveness or safety profile.

Major Interactions (Avoid): - Carbamazepine: may reduce Lacosamide plasma levels. - Phenytoin: can decrease Lacosamide exposure. - Rifampin: may increase metabolism, lowering efficacy.

Moderate Interactions (Monitor Closely): - CYP2C19 inhibitors (e.g., fluoxetine): may increase Lacosamide concentrations. - Other sodium channel blockers (e.g., lamotrigine): monitor for additive CNS effects. - Anticoagulants (e.g., warfarin): observe for potential changes in coagulation parameters.